90 compresse masticabili 500 mg 90 compresse masticabili 750 mg 90 compresse masticabili 1000 mg |
€ 208,42
€ 312,65 € 416,85 |
|
Bibliografia
1. Joy MS et al. Lanthanum carbonate. Ann Pharmacother 2006; 40:234-40.
2. Phosphate binders. The Medical Letter 2006; 48:15-16.
3. Block GA et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to emodialysis. Kidney Int 2005; 68:1815-24.
4. Qunibi WY et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004; 65:1914-26.
5.Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 2005; 16 suppl.2:S107.
6. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42:96-107.
7. Finn WF et al. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004; 62:193-201.
8. Finn WF et al. A long term, extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Cur Med Res Opin 2005; 21:657-64.
9. Hutchinson AJ et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-mounth, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100:c8-19.
10. Hutchinson AJ et al, Long term efficacy and tolerability of lanthanum carbonate: results from a 3-year study: Nephron Clin Pract 2006; 102:c61-71.
11. Finn WF on behalf of the SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006; 65:191-202.
12. Malluche HH on behalf of the SPD 405-307 Lanthanum Study Group. Improvements in renal osteodystrophy in patients with lanthanum carbonate for two years. Clin Nephrol 2008; 70:284-95.
13. D’Haese PC et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; 63 (suppl. 85):S73-8.
14. Hutchinson AJ on behalf of the SPD 405-307 Lanthanum Study Group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nepron Clin Pract 2008; 110:c15-23.
15. Freemont AJ et al. SPD 405-307 Lanthanum Study Group. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005; 64:428-37.
16. Spasovski GB et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006; 21:2217-24.
17. Altmann P et al. SPD 405-307 Lanthanum Study Group. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate therapy. Kidney Int 2007; 71:190-2.
Data di redazione 08/2008